---
id: 048
title: Macrolide QTc Prolongation and Drug Interactions
category: antimicrobials
subcategory: macrolides
tags: [macrolides, QTc-prolongation, CYP3A4, drug-interactions, torsades]
difficulty: hard
---

## Question

Which macrolides cause **QTc prolongation** and serious drug interactions via **CYP3A4 inhibition**? Use the **"ErythroClari are RISKY"** mnemonic.

## Answer

### **"ErythroClari are RISKY" Mnemonic:**

**Erythromycin and Clarithromycin are RISKY:**
- **R**ibosome binding (50S)
- **I**nhibit CYP3A4 (strong)
- **S**erious QTc prolongation risk
- **K**ill with Torsades de Pointes risk
- **Y**ield drug interactions (many)

**Azithromycin is SAFER** (minimal CYP3A4 inhibition, lower QTc risk)

### **QTc Prolongation Risk (Highest to Lowest):**

| Macrolide | QTc Risk | Mechanism | Clinical Risk |
|-----------|----------|-----------|---------------|
| **Erythromycin** | **HIGHEST** | Blocks hERG K+ channel | Torsades de Pointes (TdP) reported |
| **Clarithromycin** | High | Blocks hERG K+ channel | TdP reported |
| **Azithromycin** | Low-Moderate | Mild hERG blockade | TdP rare, controversial |

### **Risk Factors for Macrolide-Induced Arrhythmia:**

| Risk Factor | Mechanism/Notes |
|-------------|-----------------|
| **Female sex** | Longer baseline QTc |
| **Age >60 years** | Decreased renal/hepatic clearance |
| **Structural heart disease** | Pre-existing conduction abnormalities |
| **Hypokalemia/hypomagnesemia** | Potentiates QTc prolongation |
| **Concomitant QTc drugs** | Additive effect |
| **CYP3A4 inhibitors** | ↑ Macrolide levels |

### **CYP3A4 Drug Interactions (Erythro/Clarithro ONLY):**

**Macrolides INCREASE levels of these drugs (↑ toxicity):**

| Drug Class | Examples | Clinical Effect |
|------------|----------|-----------------|
| **Statins** | Simvastatin, atorvastatin | Rhabdomyolysis risk |
| **Anticoagulants** | Warfarin, rivaroxaban | ↑ INR, bleeding |
| **Immunosuppressants** | Tacrolimus, cyclosporine | Toxicity, nephrotoxicity |
| **Calcium channel blockers** | Diltiazem, verapamil | Hypotension, bradycardia |
| **Antihistamines** | Terfenadine, astemizole | **Fatal TdP** (drugs withdrawn) |
| **Benzodiazepines** | Midazolam, triazolam | Prolonged sedation |
| **Colchicine** | Colchicine | **Fatal toxicity** |

**CONTRAINDICATED Combinations:**
- Erythromycin/clarithromycin + **colchicine** (renal/hepatic impairment)
- Erythromycin/clarithromycin + **ergot alkaloids** (ergotism)
- Erythromycin/clarithromycin + **pimozide** (fatal arrhythmia)

## Key Points

### **Macrolide Selection Based on Drug Interactions:**

**Patient on CYP3A4 substrates?**
- **Avoid:** Erythromycin, clarithromycin
- **Use:** **Azithromycin** (no CYP3A4 inhibition)

**Patient with QTc >500 ms or high TdP risk?**
- **Avoid all macrolides** if possible
- If needed: Azithromycin (lowest risk)

### **Clinical Pearls:**
- **Erythromycin = most GI side effects + most drug interactions + highest QTc risk**
- **Clarithromycin = essential for H. pylori** (no azithro substitute)
- **Azithromycin = safest macrolide** for drug interactions (minimal CYP3A4 effect)
- Always check **baseline QTc** before prescribing macrolides in high-risk patients
- Correct **electrolytes (K+, Mg2+)** before starting macrolides

### **FDA Warnings:**
- **2013 FDA warning:** Azithromycin may cause fatal arrhythmias (small absolute risk)
- **Black box:** Erythromycin with terfenadine/astemizole (drugs now withdrawn)

## Sources

- [PMC4040726: Azithromycin Cardiovascular Risks and QTc]
- [PMC4072045: Erythromycin QTc Prolongation and Torsades]
- [PMC2015000: Macrolide CYP3A4 Drug Interactions]
- [StatPearls NBK551495: Macrolides]

## Media

N/A
